EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive Evaluation of the Efficacy and Safety of the Clostridioides difficile Toxoid Vaccine: A Meta‐Analysis

Muhammad Shahzil iD, Zainab Jamil iD, Saleha Azeem iD, Minahel Shehzadi iD, Aisha Shabbir, Muhammad Saad Faisal iD, Fariha Hasan iD, Muhammad Ali Khaqan iD, Ammad Javaid Chaudhary iD, Syed-Mohammed Jafri iD

Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)

DOI: 10.1155/cjid/1160340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 30.07.2026. Verfasst von Muhammad Shahzil und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey 17033, Pennsylvania, USA, psu.edu. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pennsylvania State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clostridioides difficile infection (CDI) significantly contributes to healthcare‐associated morbidity and mortality. Vaccination against C. difficile toxins may provide an effective preventive strategy, yet current data remain inconclusive. This meta‐analysis evaluates the efficacy, immunogenicity, and safety of the C. difficile toxoid vaccine.

Methods

We systematically searched PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials from inception through August 2024. Eligible studies were randomized controlled trials enrolling adults aged 50–85 years that compared genetically detoxified Clostridioides difficile toxoid vaccines (50–200 µg) with placebo and reported clinical efficacy, immunogenicity, or safety outcomes. Random‐effects meta‐analyses were performed, with risk of bias assessed using RoB 2.0 and certainty of evidence graded using GRADE. The study was prospectively registered in PROSPERO (CRD42024597465). No external funding was received for this study.

Results

Eight trials (11,717 participants) showed no significant vaccine effect on overall CDI incidence (RR = 0.86; 95% CI 0.56–1.32; I 2 = 0%) or severe CDI (RR = 0.25; 95% CI 0.02–3.75; I 2 = 71%), though severe CDI risk trended lower in vaccinated groups. Immunogenicity analyses demonstrated significant seroconversion rates for toxin A (RR = 23.28; 95% CI 7.62–71.16; I 2 = 0%) and toxin B (RR = 19.23; 95% CI 4.84–76.38; I 2 = 0%). Vaccine recipients exhibited significantly elevated geometric mean concentrations (GMCs) for antitoxin A and B antibodies across various dosing regimens, particularly at higher doses (200 µg). Local adverse events, including pain (RR = 3.02; 95% CI 2.47–3.70), swelling (RR = 8.53; 95% CI 3.15–23.14), and erythema (RR = 6.78; 95% CI 2.35–19.61), were significantly increased postvaccination, but serious systemic reactions, infections, gastrointestinal disturbances, and mortality rates showed no significant differences compared to placebo. Interpretation of vaccine efficacy is limited by imprecision of effect estimates, heterogeneity in immunogenicity reporting, and the small number of trials evaluating severe CDI outcomes.

Conclusion

Clostridioides difficile toxoid vaccines induce strong humoral immune responses and demonstrate an acceptable safety profile but do not significantly reduce the overall CDI incidence. Evidence suggests a potential role in mitigating severe disease; however, clinical benefit remains uncertain due to imprecision and heterogeneity.

Schlagwörter

Stichwörter der Autor:innen

antitoxin antibodieshumoral immunityseroconversiontoxoid immunizationvaccine safety

Autor:innen und Institutionen

  • Department of Internal Medicine, Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey 17033, Pennsylvania, USA, psu.edu.
  • Department of Medicine, King Edward Medical University, Lahore 54000, Punjab, Pakistan, kemu.edu.pk.
  • Department of Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA, umn.edu.
  • Department of Internal Medicine, Henry Ford Hospital, Detroit 48202, Michigan, USA, henryford.com.
  • Department of Internal Medicine, Cooper University Hospital, Camden 08103, New Jersey, USA, cooperhealth.org.
  • Department of Gastroenterology and Hepatology, University of Kentucky, Lexington 40506, Kentucky, USA, uky.edu.

ORCID-Profile: Muhammad Shahzil, Zainab Jamil, Saleha Azeem, Minahel Shehzadi, Muhammad Saad Faisal, Fariha Hasan, Muhammad Ali Khaqan, Ammad Javaid Chaudhary, Syed-Mohammed Jafri

Förderung

  • Pennsylvania State University

Zitieren

APA

Shahzil, M., Jamil, Z., Azeem, S., Shehzadi, M., Shabbir, A., Faisal, M. S., Hasan, F., Khaqan, M. A., Chaudhary, A. J., & Jafri, S. M. (2026). Comprehensive Evaluation of the Efficacy and Safety of the Clostridioides difficile Toxoid Vaccine: A Meta‐Analysis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/1160340

Vancouver

Shahzil M, Jamil Z, Azeem S, Shehzadi M, Shabbir A, Faisal MS, et al. Comprehensive Evaluation of the Efficacy and Safety of the Clostridioides difficile Toxoid Vaccine: A Meta‐Analysis. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/1160340

BibTeX
@article{Shahzil2026,
  author = {Shahzil, Muhammad and Jamil, Zainab and Azeem, Saleha and Shehzadi, Minahel and Shabbir, Aisha and Faisal, Muhammad Saad and Hasan, Fariha and Khaqan, Muhammad Ali and Chaudhary, Ammad Javaid and Jafri, Syed-Mohammed},
  title = {Comprehensive Evaluation of the Efficacy and Safety of the Clostridioides difficile Toxoid Vaccine: A Meta‐Analysis},
  journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cjid/1160340}
}
Kostenlos starten →